Cationic copolymers of ?,?-poly-(N-2-hydroxyethyl)-DL-aspartamide (PHEA) and ?,?-polyasparthylhydrazide (PAHy): synthesis and characterization

Synthesis of amphiphilic polyaspartamide derivatives and construction of reverse micelles

Large compound reverse micelles consisting of numerous small reverse micelles with polar cores and hydrophobic shells were constructed from amphiphilic polyaspartamide in octanol solution.

pH-Sensitive micelles with cross-linked cores formed from polyaspartamide derivatives for drug delivery

A series of polyaspartamide derivatives were synthesized by grafting O-(2-aminoethyl)-O'-methylpoly(ethylene glycol) 5000 (MPEG), 1-(3-aminopropyl) imidazole (API), and cinnamate onto polysuccinimide (PSI) with the respective degrees of substitution adjusted by the feed molar ratio. The chemical structure of the prepared polymer was confirmed using FT-IR and (1)H NMR spectroscopy. A new pH-sensitive polymeric micelle based on the synthesized polymer was prepared and characterized, and its pH-sensitive properties were characterized by the measurement of light transmittance and particle sizes at varying pH values. pH-dependent aggregation and deaggregation behavior was clearly observed in the polymer aqueous dispersion system. Photo-cross-linking of the cinnamate branches cross-linked the core of the micelles. The core cross-linked micelles showed high stability over a wider pH range and displayed obvious pH-dependent swelling-shrinking behavior instead of micelle-unimer transition behavior. This micelle system overcame the drawback of the facile disintegration of normal polymeric micelles and showed obvious delayed paclitaxel release in in vitro drug delivery experiments.

Phase transition behavior of novel pH-sensitive polyaspartamide derivatives grafted with 1-(3-aminopropyl)imidazole

New pH-sensitive polyaspartamide derivatives were synthesized by grafting 1-(3-aminopropyl)imidazole and/or O-(2-aminoethyl)-O'-methylpoly(ethylene glycol) 5000 on polysuccinimide for application in intracellular drug delivery systems. The DS of 1-(3-aminopropyl)imidazole was adjusted by the feed molar ratio, and the structure of the prepared polymer was confirmed using FT-IR and 1H NMR spectroscopy. Their pH-sensitive properties were characterized by light transmittance measurements, and the particle size and its distribution were investigated by dynamic light scattering measurements at varying pH values. The pH-sensitive phase transition was clearly observed in polymer solutions with a high substitution of 1-(3-aminopropyl)imidazole. The prepared polymers showed a high buffering capacity between pH 5 and 7, and this increased with the DS of 1-(3-aminopropyl)imidazole. The pH dependence of the aggregation and de-aggregation behavior was examined using a fluorescence spectrometer. For MPEG/imidazole-g-polyaspartamides with a DS of 1-(3-aminopropyl)imidazole over 82%, self aggregates associated with the hydrophobic interactions of the unprotonated imidazole groups were observed at pH values above 7, and their mean size was over 200 nm, while the aggregates of polymers were dissociated at pH values below 7 by the protonation of imidazole groups. These pH-sensitive polyaspartamide derivatives are potential basic candidates for intracellular drug delivery carriers triggered by small pH changes.

Poly(hydroxyethylaspartamide) derivatives as colloidal drug carrier systems

Poly(hydroxyethylaspartamide) (PHEA) derivatives bearing at the polyaminoacidic backbone poly(ethyleneglycol) (2000 or 5000 Da) or both poly(ethyleneglycol) and hexadecylalkylamine as pendant moieties were investigated as polymeric colloidal drug carriers. The ability of the PHEA derivatives to solubilize hydrophobic drugs was investigated using paclitaxel, amphotericin B and methotrexate. The results demonstrated that the drug solubility depends on both macromolecule composition and drug physicochemical properties. In particular, PEG/hexadecylalkylamine co-grafting increased significantly the solubilization properties of PHEA for the considered drugs while the conjugation of PEG only did not endow PHEA with drug carrier properties. A stability study carried out with paclitaxel/PHEA-PEG(5000)-hexadecylalkylamine demonstrated that the drug/carrier system is characterized by physicochemical instability, which is strictly related to the incubation pH. However, the carrier was found to partially prevent drug degradation. Investigations performed using murine myeloid leukaemia NFS-60 cell line showed that paclitaxel loaded PHEA-PEG(5000)-hexadecylalkylamine possesses high pharmacological activity with IC(50) value of 22.3 ng/ml. Pharmacokinetic studies carried out by intravenous administration of paclitaxel loaded PHEA-PEG(5000)-hexadecylalkylamine to Balb/c mice demonstrated that the carrier modifies the in vivo paclitaxel fate. In particular, PHEA-PEG(5000)-hexadecylalkylamine prolonged the drug distribution and elimination phase of 6 and 17 times, respectively; in addition, it increased the systemic availability (AUC) by about 30 times.